caa a22 4500 397590628 CHVBK 20180308164937.0 cr unu---uuuuu 161202e199601 xx s 000 0 eng 10.1093/jac/37.1.139 doi (NATIONALLICENCE)oxford-10.1093/jac/37.1.139 Tentative interpretive criteria and quality control parameters for in-vitro susceptibility testing of Neisseria gonorrhoeae to two fluoroquinolones (PD 131628 and grepafloxacin (OPC 17116)) [Elektronische Daten] [David L. Sewell, Arthur L. Barry, Stephen D. Allen, Peter C. Fuchs, Patrick R. Murray, Fred C. Tenover] The susceptibility of Neisseria gonorrhoeae to PD 131628 and grepafloxacin (OPC 17116) was evaluated by agar dilution and disc diffusion methods. A tentative susceptibility category for both fluoroquinolones included strains for which the MICs are ≤0.06mg/L and the zones of inhibition are ≥38mm for PD 131628 and ≥37 mm for grepafloxacin. Quality control studies with N. gonorrhoeae ATCC 49226 suggested that agar dilution MIC limits were 0.002-0.008 mg/L and 0.004-0.03 mg/L for PD 131628 and grepafloxacin, respectively. The zone size limits were 50-58 mm for PD 131628 and 44-52 mm for grepafloxacin. © 1996 The British Society for Antimicrobial Chemotherapy Brief reports nationallicence Sewell David L. The Clinical Microbiology Institute P.O. Box 947, Tualatin, Oregon 97062; USA aut Barry Arthur L. The Clinical Microbiology Institute P.O. Box 947, Tualatin, Oregon 97062; USA aut Allen Stephen D. Indiana University Medical Center Indianapolis, Indiana 46202; USA aut Fuchs Peter C. St. Vincent Hospital and Medical Center, Nosocomial Pathogens Laboratory Branch, Centers for Disease Control and Prevention Portland, Oregon 97225, Atlanta, Georgia 30333, USA aut Murray Patrick R. Barnes Hospital-Washington University, St Louis Missouri 63110, USA aut Tenover Fred C. St. Vincent Hospital and Medical Center, Nosocomial Pathogens Laboratory Branch, Centers for Disease Control and Prevention Portland, Oregon 97225, Atlanta, Georgia 30333, USA aut Journal of Antimicrobial Chemotherapy Oxford University Press 37/1(1996-01), 139-143 0305-7453 37:1<139 1996 37 jac https://doi.org/10.1093/jac/37.1.139 text/html Onlinezugriff via DOI 1 brief-communication jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jac/37.1.139 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Sewell David L. The Clinical Microbiology Institute P.O. Box 947, Tualatin, Oregon 97062; USA aut NATIONALLICENCE 700 1- Barry Arthur L. The Clinical Microbiology Institute P.O. Box 947, Tualatin, Oregon 97062; USA aut NATIONALLICENCE 700 1- Allen Stephen D. Indiana University Medical Center Indianapolis, Indiana 46202; USA aut NATIONALLICENCE 700 1- Fuchs Peter C. St. Vincent Hospital and Medical Center, Nosocomial Pathogens Laboratory Branch, Centers for Disease Control and Prevention Portland, Oregon 97225, Atlanta, Georgia 30333, USA aut NATIONALLICENCE 700 1- Murray Patrick R. Barnes Hospital-Washington University, St Louis Missouri 63110, USA aut NATIONALLICENCE 700 1- Tenover Fred C. St. Vincent Hospital and Medical Center, Nosocomial Pathogens Laboratory Branch, Centers for Disease Control and Prevention Portland, Oregon 97225, Atlanta, Georgia 30333, USA aut NATIONALLICENCE 773 0- Journal of Antimicrobial Chemotherapy Oxford University Press 37/1(1996-01), 139-143 0305-7453 37:1<139 1996 37 jac Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford